Better cell culture media, cell lines, and bioreactor strategies are responsible for yielding 10+g/l on a consistent basis. Going forward, companies will continue to implement new technologies and process designs to support emerging therapeutics. Our experts share their personal experiences and insight to help anticipate challenges and chose appropriate technologies to support your production strategies.

Meeting agenda (all times ET and subject to change)

Moderator: Susan Jones, Chief of Technical Operations, Tourmaline Bio, Inc

11:00am – 11:15am: Welcome + Meet and Greet Networking

11:15am – 11:40am: Conversation #1: Strategy Options to Support mRNA Development and Manufacturing
(Philip Probert, Technology Lead – Biologics, Centre for Process Innovation)

  • mRNAs potential to treat previously untreatable diseases
  • Ensuring consistency and scalability
  • Implementing a platform-based approach
  • Development strategy considerations

11:40am – 12:05pm: Conversation #2:  (Re)Evaluating Strategies to Improve Process Efficiency
(Robert Dream, Managing Director, HDR)

  • Having an inclusive vision of the process
  • Designing and implementing a flexible framework
  • Evaluating and implementing proper technology and skill
  • Emphasizing safety, quality, efficacy and regulatory mandates
  • The bottom line – delivering ROI

12:05pm – 12:30pm: Conversation #3: Lessons Learned Scaling-up Cell Culture Processes from Bench to GMP

  • Factors to incorporate in planning scale-up of cell culture processes
  • Understanding CHO hosts responses during scale-up
  • Strategy preparation to address expected/unexpected responses
  • Case study #1: A successful scale-up process – what went right

12:30pm – 1:30pm: Deep Dive Networking